Hooper, C, Killick, R, Lovestone, S. The GSK3 hypothesis of Alzheimer's
disease. J Neurochem
2008; 104: 1433–9.
Ishiguro, K, Shiratsuchi, A, Sato, S, Omori, A, Arioka, M, Mobayashi, S, et al. Glycogen synthase kinase 3β is identical to
tau protein kinase I generating several epitopes of paired helical
filaments. FEBS Lett
1993; 325: 167–72.
Muyllaert, D, Kremer, A, Jaworski, T, Borghgraef, P, Devijver, H, Croes, S, et al. Glycogen synthase kinase-3β, or a link
between amyloid and tau pathology?
Genes Brain Behav
2008; 7 (suppl 1):
Chuang, DM, Manji, HK. In search of the holy grail for the treatment of
neurodegenerative disorders: has a simple cation been
Hong, M, Chen, DC, Klein, PS, Lee, VM. Lithium reduces tau phosphorylation by inhibition of
glycogen synthase kinase-3. J Biol Chem
1997; 272: 25326–32.
Lovestone, S, Davis, DR, Webster, MT, Kaech, S, Brion, JP, Matus, A, et al. Lithium reduces tau phosphorylation: effects
in living cells and in neurons at therapeutic
concentrations. Biol Psychiatry
Phiel, CJ, Wilson, CA, Lee, VM, Klein, PS. GSK-3alpha regulates production of Alzheimer's
disease amyloid-beta peptides. Nature
2003; 423: 435–9.
Rockenstein, E, Torrance, M, Adame, A, Mante, M, Bar-on, P, Rose, JB, et al. Neuroprotective effects of regulators of the
glycogen synthase kinase-3β signaling pathway in a transgenic model of
Alzheimer's disease are associated with reduced amyloid precursor protein
phosphorylation. J Neurosci
2007; 27: 1981–91.
Koh, SH, Noh, MY, Kim, SH. Amyloid-β induced neurotoxicity is reduced by
inhibition of glycogen synthase kinase-3. Brain
2008; 1188: 254–62.
Nunes, PV, Forlenza, OV, Gattaz, WF. Lithium and risk for Alzheimer's disease in elderly
patients with bipolar disorder. Br J
2007; 190: 359–60.
Kessing, LV, S⊘ndergård, L, Forman, JL, Andersen, PK. Lithium treatment and risk of
dementia. Arch Gen Psychiatry
2008; 65: 1331–5.
Kessing, LV, Forman, JL, Andersen, PK. Does lithium protect against
Macdonald, A, Briggs, K, Poppe, M, Higgins, A, Velayudhan, L, Lovestone, S. A feasibility and tolerability study of lithium in
Alzheimer's disease. Int J Geriatr
2008; 23: 704–11.
Hampel, H, Ewers, M, Bürger, K, Annas, P, Mörtberg, A, Bogstedt, A, et al. Lithium trial in Alzheimer's disease: a
randomized, single-blind, placebo-controlled, multicenter 10-week
study. J Clin Psychiatry
2009; 70: 922–31.
Petersen, RC, Smith, GE, Waring, SC, Ivnik, RJ, Tangalos, EG, Kokmen, E. Mild cognitive impairment: clinical characterization
and outcome. Arch Neurol
1999; 56: 303–8.
Diniz, BS, Nunes, PV, Yassuda, MS, Pereira, FS, Flaks, MK, Viola, LF, et al. Mild cognitive impairment: cognitive
screening or neuropsychological assessment?
Rev Bras Psiquiatr
2008; 30: 316–21.
Roth, M, Tym, E, Mountjoy, CQ, Huppert, FA, Hendrie, H, Verina, S, et al. CAMDEX. A standardised instrument for the
diagnosis of mental disorder in the elderly with special reference to the
early detection of dementia. Br J
Morris, JC. The Clinical Dementia Rating (CDR): current version
and scoring rules. Neurology
1993; 43: 2412–4.
Rosen, WG, Mohs, RC, Davis, KL. A new rating scale for Alzheimer's
disease. Am J Psychiatry
1984; 141: 1356–64.
Morris, JC, Mohs, RC, Rogers, H, Fillenbaum, G, Heyman, A. Consortium to Establish a Registry for Alzheimer's
Disease (CERAD) clinical and neuropsychological assessment of Alzheimer's
disease. Psychopharmacol Bull
1988; 24: 641–52.
Wechsler, D. Wechsler Adult Intelligence Scale – Third Edition,
WAIS-III. The Psychological
Reitan, RM. Halstead–Reitan Neuropsychological Test Battery.
Reitan Neuropsychology Laboratory Press,
Vellas, B, Andrieu, S, Sampaio, C, Wilcock, G, et al. Disease-modifying trials in Alzheimer's
disease: a European task force consensus. Lancet
Vellas, B, Andrieu, S, Sampaio, C, Coley, N, Wilcock, G, et al. Endpoints for trials in Alzheimer's disease:
a European task force consensus. Lancet
2008; 7: 436–50.
Diniz, BS, Pinto Júnior, JA, Forlenza, OV. Do CSF total tau, phosphorylated tau, and
beta-amyloid 42 help to predict progression of mild cognitive impairment
to Alzheimer's disease? A systematic review and meta-analysis of the
literature. World J Biol Psychiatry
2008; 9: 172–82.
Bhat, RV, Budd Haeberlein, SL, Avila, J. Glycogen synthase kinase 3: a drug target for CNS
therapies. J Neurochem
2004; 89: 1313–7.
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new
comprehensive rating scale for psychotropic drugs and a corss-sectional
study of side effects in neuroleptic-treated patients.
Acta Psychiatr Scand
1987; 334 (suppl):